New light for science: synchrotron radiation in structural medicine

Trends in Biotechnology

Volumn 24, Issue 11, 2006, Pages 500-508

  Sorensen, Thomas L M ^a   McAuley, Katherine E ^a   Flaig, Ralf ^a   Duke, Elizabeth M H ^a  

^a DIAMOND LIGHT SOURCE LTD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MACROMOLECULAR CRYSTALLOGRAPHY (MX); STRUCTURAL MEDICINE;

CRYSTAL STRUCTURE; CRYSTALLOGRAPHY; SYNCHROTRON RADIATION; THREE DIMENSIONAL; X RAY ANALYSIS;

MEDICINE;

6 (2,6 DICHLOROPHENYL) 8 METHYL 2 (3 METHYLTHIOANILINO) 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; ABELSON KINASE; ATORVASTATIN; BICALUTAMIDE; CIPROFLOXACIN; CYCLOPROPANECARBOXYLIC ACID [4 [4 (4 METHYL 1 PIPERAZINYL) 6 (5 METHYL 2H PYRAZOL 3 YLAMINO) 2 PYRIMIDINYLTHIO]PHENYL]AMIDE; IMATINIB; MALATE SYNTHASE; MEMBRANE PROTEIN; PROTEIN TYROSINE KINASE INHIBITOR; RALOXIFENE; RISEDRONIC ACID; RITONAVIR; ROSIGLITAZONE; TRASTUZUMAB; UNCLASSIFIED DRUG; ZANAMIVIR;

AMINO TERMINAL SEQUENCE; BACTERIAL INFECTION; BLAST CELL CRISIS; BREAST CANCER; CANCER REGRESSION; CHROMOSOME TRANSLOCATION; CHRONIC MYELOID LEUKEMIA; CRYSTAL STRUCTURE; CRYSTALLIZATION; CRYSTALLOGRAPHY; DRUG DESIGN; DRUG TARGETING; ELECTRON; ENZYME STRUCTURE; GENETIC CODE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; IMAGE QUALITY; INFLUENZA; MACROMOLECULE; MOLECULAR BIOLOGY; MYCOBACTERIUM TUBERCULOSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OSTEOPOROSIS; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SYNCHROTRON RADIATION; THREE DIMENSIONAL IMAGING; TUBERCULOSIS; X RAY CRYSTALLOGRAPHY; X RAY DIFFRACTION;

ANTITUBERCULAR AGENTS; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; FUSION PROTEINS, BCR-ABL; HUMANS; HYPOGLYCEMIC AGENTS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKEMIA, MYELOID, CHRONIC; MEMBRANE PROTEINS; MODELS, MOLECULAR; MULTIPROTEIN COMPLEXES; PROTEIN CONFORMATION; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; SYNCHROTRONS; TUBERCULOSIS, PULMONARY; X-RAYS;

EID: 33749558124     PISSN: 01677799     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tibtech.2006.09.006     Document Type: Review

References (69)

1. + conduction and selectivity. Science 280 (1998) 69-77
2. Sorensen T., et al. Phosphoryl transfer and calcium ion occlusion in the calcium pump. Science 304 (2004) 1672-1675
3. Ban N., et al. The complete atomic structure of the large ribosomal subunit at 2.4 Å resolution. Science 289 (2000) 905-920
4. Wimberly B.T., et al. Structure of the 30S ribosomal subunit. Nature 407 (2000) 327-339
5. Schluenzen F., et al. Structure of functionally activated small ribosomal subunit at 3.3 angstroms resolution. Cell 102 (2000) 615-623
6. Yusupov M.M., et al. Crystal structure of the ribosome at 5.5 A resolution. Science 292 (2001) 883-896
7. Brown D.G., and Flocco M.M. Structure determination - crystallography for structure-based drug design. In: Hubbard R. (Ed). Structure-Based Drug Discovery - An Overview (2006), Royal Society of Chemistry 32-53
8. Deininger M., et al. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 105 (2005) 2640-2653
9. Elder F.R., et al. Radiation from electrons in a synchrotron. Phys. Rev. 71 (1947) 829-830
10. Tomboulian D.H., and Hartman P.L. Spectral and angular distribution of ultraviolet radiation from the 300-MeV Cornell synchrotron. Phys. Rev. 102 (1956) 1423-1447
11. Rosenbaum G., et al. Synchrotron radiation as a source for X-ray diffraction. Nature 230 (1971) 434-437
12. Wlodawer A., and Vondrasek J. Inhibitors of HIV-1 protease: a major success of structure-assisted drug design. Annu. Rev. Biophys. Biomol. Struct. 27 (1998) 249-284
13. Ren J., and Stammers D.K. HIV reverse transcriptase structures: designing new inhibitors and understanding mechanisms of drug resistance. Trends Pharmacol. Sci. 26 (2005) 4-7
14. Garman E., and Laver G. Controlling influenza by inhibiting the virus's neuraminidase. Curr. Drug Targets 5 (2004) 119-136
15. Sawyers C.L. Chronic myeloid leukemia. N. Engl. J. Med. 340 (1999) 1330-1340
16. Deininger M.W.N., et al. The molecular biology of chronic myeloid leukemia. Blood 96 (2000) 3343-3356
17. Canitrot Y., et al. Mutator phenotype of BCR-ABL transfected Ba/F3 cell lines and its association with enhanced expression of DNA polymerase beta. Oncogene 18 (1999) 2676-2680
18. Wong S., and Witte O.N. The BCR-ABL story: bench to bedside and back. Annu. Rev. Immunol. 22 (2004) 247-306
19. Kantarjian H.M., et al. Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenic responses. Blood 101 (2003) 97-100
20. Druker B.J., et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med. 344 (2001) 1038-1042
21. Sawyers C.L., et al. Imatinib induces hematologic and cytogenic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 99 (2002) 3530-3539
22. Hochhaus A., et al. Molecular and chromosomal mechanisms of resistance to imatinib (ST1571) therapy. Leukemia 16 (2002) 2190-2196
23. Shah N.P., et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (ST1571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2 (2002) 117-125
24. Corbin A.S., et al. Several Bcr-Abl kinase domain mutants associated with imatinib meylate resistance remain sensitive to imatinib. Blood 101 (2003) 4611-4614
25. Cowan-Jacob S.W., et al. Imatinib (STI571) resistance in chronic myelogenous leukemia: molecular basis of the underlying mechanisms and potential strategies for treatment. Mini Rev. Med. Chem. 4 (2004) 285-299
26. Schindler T., et al. Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase. Science 289 (2000) 1938-1942
27. Azam M., et al. Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell 112 (2003) 831-843
28. Nagar B., et al. Structural basis for the autoinhibition of c-Abl tyrosine kinase. Cell 112 (2003) 859-871
29. Nagar B., et al. Crystal structure of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res. 62 (2002) 4236-4243
30. Young M.A., et al. Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the aurora kinase inhibitor VX-680. Cancer Res. 66 (2006) 1007-1014
31. Shah N.P., et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305 (2004) 399-401
32. Burgess M.R., et al. Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 3395-3400
33. Lee F.Y., et al. Dasatinib (BMS-354825) overcomes multiple mechanisms of imatinib resistance in chronic myeloid leukemia (CML). Blood 106 (2005) Abstract 1994
34. Manley P.W., et al. Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia. Biochim. Biophys. Acta 1754 (2005) 3-13
35. Noble M.E.M., et al. Protein kinase inhibitors: insights into drug design from structure. Science 303 (2004) 1800-1805
36. Dye C., et al. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. J. Am. Med. Assoc. 282 (1999) 677-686
37. Dye C., et al. Evolution of tuberculosis control and prospects for reducing tuberculosis incidence, prevalence, and deaths globally. J. Am. Med. Assoc. 293 (2005) 2767-2775
38. Corbett E.L., et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch. Intern. Med. 163 (2003) 1009-1021
39. McKinney J.D., et al. Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lysase. Nature 406 (2000) 735-738
40. Smith C.V., et al. Biochemical and structural studies of malate synthase from Myocbacterium tuberculosis. J. Biol. Chem. 278 (2003) 1735-1743
41. Smith C.V., et al. TB drug discovery: addressing issues of persistence and resistance. Tuberculosis (Edinb.) 84 (2004) 45-55
42. Hendrickson W.A. Determination of macromolecular structures from anomalous diffraction of synchrotron radiation. Science 254 (1991) 51-58
43. Huang C.-C., et al. Crystal structures of mycolic acid cyclopropane synthases from Mycobacterium tuberculosis. J. Biol. Chem. 277 (2002) 11559-11569
44. Arcus V.L., et al. The potential impact of structural genomics on tuberculosis drug discovery. Drug Discov. Today 11 (2006) 28-34
45. Gonzalez A. Optimizing data collection for structure determination. Acta Crystallogr. D: Biol. Crystallogr. 59 (2003) 1935-1942
46. Pusey M.L., et al. Life in the fast lane for protein crystallization and X-ray crystallography. Prog. Biophys. Mol. Biol. 88 (2005) 359-386
47. Pohl E., et al. Automation of the EMBL Hamburg protein crystallography beamline BW7B. J. Synchrotron Radiat. 11 (2004) 372-377
48. Snell G., et al. Automated sample mounting and alignment system for biological crystallography at a synchrotron source. Structure 12 (2004) 537-545
49. Arzt S., et al. Automation of macromolecular crystallography beamlines. Prog. Biophys. Mol. Biol. 89 (2005) 124-152
50. Hummer G., et al. Unveiling functional protein motions with picosecond X-ray crystallography and molecular dynamics simulations. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 15330-15334
51. Schotte F., et al. Picosecond time-resolved X-ray crystallography: probing protein function in real time. J. Struct. Biol. 147 (2004) 235-246
52. Pierce K.L., et al. Seven-transmembrane receptors. Nat. Rev. Mol. Cell Biol. 3 (2002) 639-650
53. Lundstrom K. Structural genomics of GPCRs. Trends Biotechnol. 23 (2005) 103-108
54. In: Iwata S. (Ed). Methods and Results in Crystallization of Membrane Proteins (2003), International University Line
55. Kawate T., and Gouaux E. Fluorescence-detection size-exclusion chromatography for precrystallization screening of integral membrane proteins. Structure 14 (2006) 673-681
56. Cusack S., et al. Small is beautiful: protein microcrystallography. Nat. Struct. Biol. 5 Suppl. (1998) 634-637
57. Perrakis A., et al. Protein microcrystals and the design of a microdiffractometer: current experience and plans at EMBL and ESRF/ID13. Acta Crystallogr. D Biol. Crystallogr. 55 (1999) 1765-1770
58. Riekel C. Recent developments in micro-diffraction on protein crystals. J. Synchrotron Radiat 11 (2004) 4-6
59. Riekel C., et al. Protein crystallography microdiffraction. Curr. Opin. Struct. Biol. 15 (2005) 556-562
60. Nicolini C., and Pechkova E. Structure and growth of ultrasmall protein microcrystals by synchrotron radiation: I. MicroGISAXS and microdiffraction of P450scc. J. Cell. Biochem. 97 (2006) 544-552
61. Nelson R., et al. Structure of the cross-β spine of amyloid-like fibrils. Nature 435 (2005) 773-778
62. Gonzalez A., and Nave C. Radiation damage in protein crystals at low temperature. Acta Crystallogr. D Biol. Crystallogr. 50 (1994) 874-877
63. Weik M., et al. Specific chemical and structural damage to proteins produced by synchrotron radiation. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 623-628
64. Owen R.L., et al. Experimental determination of the radiation dose limit for cryocooled protein crystals. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 4912-4917
65. Teng T.Y., and Moffat K. Radiation damage of protein crystals at cryogenic temperatures between 40 K and 150 K. J. Synchrotron Radiat. 9 (2002) 198-201
66. Taylor N.R., et al. Dihydropyrancarboxamides related to zanamivir: a new series of inhibitors of influenza virus sialidases. 2. Crystallographic and molecular modeling study of complexes of 4-amino-4H-pyran-6-carboxamides and sialidase from influenza virus types A and B. J. Med. Chem. 41 (1998) 798-807
67. Atwell S., et al. Novel mode of gleevec binding is revealed by the structure of spleen tyrosine kinase. J. Biol. Chem. 279 (2004) 55827-55832
68. Kempf D.J., et al. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 2484-2488
69. Sohoel H., et al. Natural products as starting materials for development of second-generation SERCA inhibitors targeted towards prostate cancer cells. Bioorg. Med. Chem. 14 (2006) 2810-2815